All type of patients: 2 trials - JAVELIN Lung 200 - JAVELIN Lung 100
| avelumab vs docetaxel | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | Grade 3–5 drug-related AEs | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| avelumab vs platinum-based CT | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | Grade 3–5 drug-related AEs | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
First line: 1 trials - JAVELIN Lung 100
| avelumab vs platinum-based CT | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | Grade 3–5 drug-related AEs | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Second line : 1 trials - JAVELIN Lung 200
| avelumab vs docetaxel | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | Grade 3–5 drug-related AEs | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 1 trials - JAVELIN Renal 101
| avelumab + axitinib vs sunitinib | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 1 trials - JAVELIN Bladder 100
| avelumab vs control | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | complete response (CR) | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data | | Grade 3–5 drug-related AEs | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
